高效整合成本数据，提前预警风险；实时掌握资金流向，提升管控能力……北京同仁堂科技发展股份有 限公司（以下简称"同仁堂科技公司"）依托"浪潮GScloud"及"大数据分析平台"打造的智能财务系统如 同一根指挥棒，正灵活高效地统筹着成本、资金等企业核心生产要素的流动。 在资金管理方面，该系统与银行深度对接，可实时监控全系统资金流入流出、预算执行、债务结构、收 付款动态等情况，如同拥有资金流动的"全景驾驶舱"。"现在开经营会，大屏一开，资金状况一目了 然，决策更有底气。"企业财务部门主管表示。 此外，该系统在差旅审批、发票识别、报账校验等方面也开发了大量智能应用，实现了用机器"看懂"业 务单据，也让以往繁琐复杂的流程"友好"起来。 "统一的核算标准、实时的资金监控、穿透式的成本管理，使总部对全系统实现了'如臂使指'的强管 控。"企业相关负责人表示，对数据的实时监控，实现了风险从"事后发现"到"事中拦截"和"事前预 警"的积极转变，从这个意义上讲，财务数据也正逐渐转化为驱动企业高质量发展的战略性资源。目 前，企业基于该系统平台，已部署近百个分析模型，覆盖预算分析、产销协同、盈利洞察、效率评估等 多个业务单元，为管理层 ...

7月21日，中成药龙头企业沃华医药(002107)发布2025年半年报，在医疗改革、原材料成本上涨的背景 下，沃华医药上半年实现盈利同比增长超3倍。近年来，沃华医药持续推行精细化管理，以学术、研发 为抓手，促进业绩增长。与此同时，医疗行业正迎国家医疗强基工程的重要机遇，沃华医药有望借此进 一步拓展基层市场。 业绩报告显示，今年上半年，沃华医药实现营业收入4.25亿元，同比增长7.64%；净利润4467.64万元， 同比增长303.16%。同时拟向全体股东每10股派发现金红利1.2元(含税)。 近年来，沃华医药着力推动公司产品进入各项临床指南、专家共识和诊疗方案。今年上半年，沃华医药 四大独家医保支柱产品新增6项，共计获得93项权威教材、临床指南、临床路径诊疗方案及专家共识的 推荐。 值得关注的是，今年以来，我国医疗卫生强基工程促进优质医疗资源下沉和区域均衡布局，为沃华医药 提供了政策机遇。 据悉，2025年2月以来，我国已在2188个县（市、区）推进紧密型县域医共体建设。目前，心可舒片已 进入县域医共体目录近300个，仅2025年第二季度，新增进入41个目录。同时，沃华医药其他医保品种 也在努力通过进入相关目 ...

Core Viewpoint - The event "Rational Investment Accompanying Me - Entering the Listed Company Jilin Aodong" aims to enhance communication between investors and the company, promoting rational, value, and long-term investment concepts [1] Group 1: Company Overview - Jilin Aodong has been recognized as a leading company in the Chinese pharmaceutical industry, ranking among the top 100 pharmaceutical companies in China for 11 consecutive years and awarded as one of the 500 most valuable brands in China [1][2] - The company has transformed from a state-owned deer farm to a publicly listed pharmaceutical company, expanding its business into various fields including traditional Chinese medicine, chemical drugs, health products, and food [2][3] - Jilin Aodong's product portfolio includes well-known products such as Anshen Bnnao Liquid and Xiaoer Chaigui Fever Oral Liquid, supported by a robust product hierarchy aimed at driving performance growth [2][3] Group 2: Business Strategy and Financial Performance - The company operates with a "pharmaceutical + finance + health" multi-wheel drive strategy, leveraging financial investments to enhance its core pharmaceutical business and extend its reach into biopharmaceuticals and internet healthcare [3] - Jilin Aodong holds 628 production approval numbers, with over 300 for both traditional Chinese medicine and chemical drugs, indicating a strong regulatory compliance and product diversity [3] - The company plans to maintain a stable dividend policy, with potential increases as operational performance improves, and is actively working on enhancing sales in its enzyme product line and chain pharmacy profitability [4] Group 3: Investor Engagement and Future Outlook - The event facilitated direct interaction between investors and the company's management, allowing for discussions on dividend policies, product sales, and profitability of chain pharmacies [4] - The company aims to continue its commitment to innovation and responsibility, striving for a more prosperous future while contributing to the development of the Chinese pharmaceutical industry [5]

三十出头，白发却悄悄爬上了鬓角；镜子前，一抓就是一撮白，染了黑却越长越白。 你以为是遗传，其实可能是身体虚了。 中医认为："发为血之余"。头发的健康，取决于气血是否充足，很多年轻人早生白发，并非自然衰老， 而是源于气血不足，导致毛囊营养供应不足，黑色素减少，最终出现"未老先白"。 针对这类"血虚型"白发问题，天昌元推出了专业中成药产品——六君生发胶囊。它以中医理论为基础， 从调肾养血入手，从根源改善白发多、头发早白等问题，为许多白发困扰者提供了科学、安全的调理方 案。 1、白发早生，问题根源在"血虚" 在快节奏、高压力的现代生活中，不少年轻人长期熬夜、焦虑过劳，加之饮食不节、体质下降，常出 现： 洗头时大量掉发，新发细软； 面色无华、易疲劳。 中医辨证来看，这正是典型的血虚型发质问题，必须从"补血养血"入手，而非单纯靠外用或染发掩盖。 2、六味核心药材，补血养血协同生发 天昌元六君生发胶囊精选六味药材，以补血养血、生发乌发为核心目标，配伍精妙： 当归、熟地黄：养血补血、润养发根，是改善血虚白发的常用中药； 头发早白、干枯、易断； 何首乌、侧柏叶：滋阴补血、乌须黑发，改善肝肾不足引起的早白发； 胱氨酸：参与角蛋 ...

Group 1 - The core point of the news is that Fujian Cosunter Pharmaceutical Co., Ltd. plans to issue A-shares to specific investors in 2025, aiming to raise a total of up to 976.87 million yuan for various projects, including innovative drug research and development [2][5][10] - The issuance plan has been approved by the company's board and shareholders, but it still requires approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [2][3] - The company intends to issue no more than 47,780,100 shares, which will not exceed 30% of the total share capital before the issuance [5][6] Group 2 - The funds raised will be allocated as follows: approximately 598.38 million yuan for innovative drug R&D, about 88.49 million yuan for traditional Chinese medicine industrialization, and 290 million yuan for working capital [5][10] - The pricing for the shares will be based on the average trading price over the 20 trading days prior to the pricing date, with a minimum price set at 80% of that average [4][5] - The issuance will not change the controlling shareholder or the actual controller of the company, and the profits accumulated before the issuance will be shared by both new and existing shareholders [6][10] Group 3 - The company has faced continuous losses, with net profits of -132.18 million yuan, -354.23 million yuan, -199.54 million yuan, and -30.42 million yuan in recent years, primarily due to high R&D costs and the impact of national drug procurement policies [8][10] - The company is undergoing a strategic transformation from generic drugs to innovative drugs, which requires significant investment and carries inherent risks associated with drug development [9][10] - The company has committed to measures to mitigate the dilution of immediate returns for existing shareholders post-issuance, although this does not guarantee future profits [6][7]

-2025 下半年医药产业政策展望 摘要: 2025.07.10 保基本、强创新 慧博投研",请勿外传! 产业研究中心 | CR | 丁丹(分析师) | | --- | --- | | 8 | 021-38676666 | | 登记编号 | S0880514030001 | | ર | 贺文斌(分析师) | | 8 | 021-38676666 | | 登记编号 | S0880525040034 | | S | 张拓(分析师) | | 2 | 021-38676666 | | 登记编号 | S0880523090003 | 请务必阅读正文之后的免责条款部分 1 of 21 o 政策主线为保基本和强创新。从近期顶层设计政策和地方、部委具体文件 发布、政策实施看,整体沿着"保基本、强创新"两条主线。1)保基本一 一保障人民群众基本的医疗需求,通过医保目录等措施提升医疗产品和服 务的可及性,通过集采降价等措施匹配可支付性,同时通过纠风整顿等措 施规范医疗市场、保障政策实施效果。2)强创新 -- 加强创新,从产品评 审、医保准入、多元支付、国际推广、融资等全链条支持创新,获取产业 升级和满足更多未被满足临床需求的经济 ...

事件：2025 年H1，公司营业收入同比增长约12%；归母净利润预计3.68~3.88 亿元（+24.3%~31.06%， 同比增长24.3%~31.06%，下同），扣非归母净利润3.66~3.86 亿元（+25.36%~32.21%）。单Q2 季度来 看，公司实现营收7.8 亿元（+2.7%），预计归母净利润1.87~2.07 亿元（+21%~34%），扣非归母净利 润1.85~2.05 亿元（+25%~39%）。扣除股权激励费用影响，公司上半年归母净利润3.8~4.0 亿元，同比 增长28.9%~35.7%。超此前我们的利润预期。 风险提示：集采后放量不及预期风险，行业政策风险，市场竞争加剧风险等。 盈利预测与投资评级：我们维持预计2025-2027 年公司归母净利润为6.55/8.41/10.41 亿元，对应PE 估值 为20/16/13X。展望下半年，随着广东联盟扩围接续以及湖北中成药集采的陆续执行，公司乌灵胶囊、 百令系列放量均有望提速。维持"买入"评级。 核心产品稳健增长，院外OTC 开拓成效显著：分产品来看，乌灵系列维持稳健增长，百令系列增速有 所提升。单Q2 季度收入放缓的原因，主要系2024 ...

中国经济网北京7月7日讯粤万年青（301111）(301111.SZ)近日披露《关于控股股东、实际控制人之一致 行动人股份减持计划的预披露公告》和《关于持股5%以上股东股份减持计划的预披露公告》。 根据公告，公司控股股东、实际控制人之一致行动人汕头市银康企业管理咨询合伙企业(有限合伙)(以下 简称"银康管理")和股东合和投资控股(广州)合伙企业(有限合伙)(以下简称"合和投资")计划在减持计划 公告披露之日起15个交易日后的3个月内以集中竞价交易、大宗交易方式合计减持公司股份不超过 9,600,000股，减持比例不超过公司总股本的6.00%。 粤万年青首次公开发行股票募集资金总额为4.19亿元，扣除发行费用后募集资金净额为3.70亿元。粤万 年青最终募集资金净额比原计划多909.01万元。粤万年青于2021年12月2日披露的招股说明书显示，该 公司拟募集资金3.61亿元，分别用于中成药生产扩建项目、研发中心建设项目和补充营运资金项目。 粤万年青首次公开发行股票的发行费用总额为4949.19万元，其中，保荐及承销费用3318.00万元。 粤万年青的控股股东为广东金欧健康科技有限公司，实际控制人为欧先涛、李映华。 ...

炎炎夏日，被蚊虫叮咬是常事，涂抹一点清凉油，便能迅速止痒消肿；咽喉肿痛时，含服一片西瓜霜含 片，冰凉的感觉会让嗓子舒服很多。在这些我们熟知的药物中，都有一个神秘的"功臣"——冰片。 冰片被誉为中药领域里的"清凉使者"，不仅能开窍醒神，还能消肿止痛，是传统中药里的珍贵之品。 从"龙脑香"到现代冰片 打开家庭药箱，含冰片的药品随处可见：缓解咽喉肿痛的西瓜霜含片、提神醒脑的风油精……这些药物 能清凉消肿止痛、快速起效，都离不开冰片的功劳。 在中成药领域，冰片更是"明星成分"：在安宫牛黄丸中，它能够开窍醒神，可用于中风昏迷患者的急 救；在复方丹参滴丸和速效救心丸中均含有冰片，可借助它来促进药物吸收，迅速缓解心绞痛症状；还 有一些外用药物如痔疮膏、滴眼液中也加入冰片，发挥清凉消肿止痛的功效。 但是，这并不意味着冰片就是能"包治百病"的神药。 警惕"万能药"陷阱 冰片的历史，最早可追溯到南北朝时期。当时东南亚的龙脑香树树脂传入中国，因其"状如云母，色如 冰雪"，古人称之为"神药"，将其命名为"龙脑"，也就是现在所说的冰片。当时，获取龙脑极其困难， 其产量也极低，因此只有贵族才能使用这味药材。 到了唐代，冰片更是受到了皇室 ...

Core Points - The company aims to protect the legal rights of shareholders, employees, and creditors while adhering to various laws and regulations [2][4] - The company was established as a joint-stock company in accordance with the Company Law and has a registered capital of RMB 1,371,470,262 [3][6] - The company emphasizes the importance of the Communist Party's leadership in its governance and operations [5][6] Company Overview - The registered name of the company is Beijing Tong Ren Tang Co., Ltd., with its English name being the same [3] - The company is located in Daxing District, Beijing, with a postal code of 102629 [3] - The company was approved for its initial public offering of 50 million shares in May 1997 [3][4] Governance Structure - The chairman represents the company in executing its affairs and is the legal representative [3][4] - The company has established a party organization that plays a core leadership role, ensuring the integration of party leadership and corporate governance [5][6] - The company’s articles of association serve as a legally binding document for the rights and obligations of shareholders and management [4][5] Business Objectives and Scope - The company's business objective is to uphold the traditional values of Tong Ren Tang while promoting high-quality development in the traditional Chinese medicine industry [6] - The company is engaged in the manufacturing and processing of traditional Chinese medicine, cosmetics, and various other related services [6][7] Share Structure - The company has issued a total of 1,371,470,262 shares, all of which are ordinary shares [7][8] - The issuance of shares follows principles of openness, fairness, and justice, ensuring equal rights for all shareholders [7][8] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends, participate in shareholder meetings, and supervise the company's operations [14][15] - Shareholders are obligated to comply with laws and regulations and cannot withdraw their capital except as legally permitted [18][19] Shareholder Meetings - The company holds annual shareholder meetings within six months after the end of the fiscal year [55] - Special meetings can be convened under specific circumstances, such as when requested by shareholders holding more than 10% of the shares [56][57] Financial Transactions and Approvals - Major financial transactions, including asset purchases and external investments, require shareholder approval if they exceed specified thresholds [47][48][49] - The company must disclose significant financial guarantees and related transactions to ensure transparency [51][52]